MLICM
GALT icon

Metropolitan Life Insurance Company (MetLife)’s Galectin Therapeutics GALT Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-14,775
Closed -$204K – 2692
2014
Q2 		$204K Buy
+14,775
New +$184K ﹤0.01% 2496

Other funds holding GALT

CCA
Catalyst Capital Advisors Huntington, New York $6.03B AUM 24.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s GALT Position: Q3 2014 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Galectin Therapeutics (GALT) in Q3 2014, closing a stake of 14,775 shares — an estimated $204K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in GALT in Q2 2014 and held it in 1 quarter. The position peaked at $204K in Q2 2014. 63 funds tracked by Wall St. Rank hold GALT as of Q3 2014.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Galectin Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 14,775 Galectin Therapeutics shares in Q3 2014, an estimated $204K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Galectin Therapeutics in Q2 2014 and held it in 1 quarter.
  • Metropolitan Life Insurance Company (MetLife)'s Galectin Therapeutics position peaked at $204K in Q2 2014.
  • 63 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2014.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2014, filed 10 Nov 2014.